



Ocera Therapeutics, Inc.
Investor Relations Department
5001 S. Miami Boulevard,
Suite 300
Durham, NC 27703
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: OCRX

Last Trade:	1.72
Trade Time:	3:59 PM ET Nov 22, 2017
Change:	-0.02 (-1.149%)
Day Range	1.71 - 1.75
52-Week Range	0.52 - 2.95
Volume	320,868

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.


Company Profile

[Ocera Therapeutics](#)

(NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Nov 2, 2017

[Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy](#)

Oct 20, 2017

[Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®](#)

Aug 23, 2017

[Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017](#)

Aug 1, 2017

[Ocera Therapeutics Reports Second Quarter 2017 Financial Results](#)

Jun 1, 2017

[Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 14, 2017

[Annual Report \(10-K\)](#)

Apr 25, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 14, 2017

[Quarterly Report \(10-Q\)](#)

Aug 1, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)